Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.
Regulatory Catalyst | Potential BLA approval for Avance Nerve Graft in September 2025 could be a game-changer, with analyst price targets ranging from $24 to $26. |
Strategic Growth Plan | Explore AxoGen's ambitious 15-20% revenue CAGR target for 2025-2028, driven by high-potential accounts and operational efficiencies. |
Innovative Portfolio | Discover AxoGen's unique product lineup, including AxoGuard HA+ and Avive+, positioned with limited biologic competition in sizable markets. |
Nerve Repair Pionee | AxoGen leads in peripheral nerve injury solutions, with a $5.6 billion addressable market and 17.8% year-over-year revenue growth, showcasing strong market potential. |
Metrics to compare | AXGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAXGNPeersSector | |
---|---|---|---|---|
P/E Ratio | −81.1x | −2.2x | −0.5x | |
PEG Ratio | −1.41 | 0.18 | 0.00 | |
Price / Book | 7.8x | 1.1x | 2.6x | |
Price / LTM Sales | 4.3x | 1.6x | 3.0x | |
Upside (Analyst Target) | 39.7% | 224.1% | 53.8% | |
Fair Value Upside | Unlock | 11.9% | 9.2% | Unlock |